Perverse incentives - HIV prevention and the 340B drug pricing program

New England Journal of Medicine

28 May 2022 - A decade after preexposure prophylaxis against HIV became available, less than a quarter of people in the United States who could benefit from PrEP are taking it. 

The failure is a perverse outcome of a system that relies on high drug prices to fund HIV prevention.

Read New England Journal of Medicine Perspective

Michael Wonder

Posted by:

Michael Wonder